Recently, according to the 2022 China Biomedical Industrial Park Competitiveness Evaluation and Analysis Report and the 2021 China Biomedical Park Development Competitiveness Ranking List, released by the 2022 China Biotech Innovation Conference, Chengdu Hi-tech Industrial Development Zone in Southwest China's Sichuan Province ranked third in the overall competitiveness of the domestic parks, and top the first echelon of national biomedical parks.

A panorama of Chengdu Tianfu International Bio-town Photos: Courtesy of Department of the Party and the masses affairs of Chengdu Hi-tech Industrial Development Zone

As the most innovative emerging industry, the biomedical industry has become an important support for Chengdu to build a modern industrial system with international competitiveness and regional driving force. It is understood that with the development of biomedical industry and an industrial scale of more than 100 billion yuan($14.2 billion), Chengdu Hi-tech Industrial Development Zone is accelerating the cluster construction of key projects such as Chengdu Tianfu International Bio-town and Frontier Medical Center, and constantly improving and strengthening the energy level of the biomedical industry.

At the end of October, the World Top 500 General Electric (GE) Medical China Precision Medical Industrialization Base Project was signed and settled in Chengdu Hi-tech Industrial Development Zone, which is the first industrialization base in Sichuan established by a multinational top 500 medical enterprise.

Chengdu Hi-tech Industrial Development Zone Photo: Courtesy of Department of the Party and the masses affairs of Chengdu Hi-tech Industrial Development Zone

In recent years, the Zone has completed the construction of the first phase of the national pilot demonstration base for the transfer and transformation of sci-tech achievements in major new drug discoveries, achieved 29 breakthroughs in core technologies, and undertaken more than 1,000 services for the transfer and transformation of new drug achievements, thanks to the continuous promotion of high-quality development of the high-performance medical device industry and the layout of subdivisions such as in vitro diagnosis, implantable intervention products and medical materials, intelligent diagnosis and treatment equipment, as well as the development of innovative medicine. Chengdu Hi-tech Industrial Development Zone has also made important breakthroughs in biomedical innovation.

It has introduced 109 functional platforms, including the international parallel laboratory of biomedicine and the trillion level DNA new drug screening platform for Chengdu HitGen, the pharmaceutical company, to build a full chain technology innovation platform covering target discovery, drug screening, clinical trials and other new drug research and development.

As of 2022, the Chengdu Hi-tech Industrial Development Zone, with nine listed biomedical enterprises establishing operations in the area, has guided the establishment of five medical and health sub funds, with a total fund size of 6.6 billion yuan($939,314,640), which has promoted the successful implementation of 10 enterprises within 2022 alone.